Experimental virus therapy takes on advanced tumors in early trial

NCT ID NCT05165433

Completed Disease control Sponsor: Akamis Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new treatment called NG-350A, a virus designed to target tumors and boost immune activity, combined with the immunotherapy drug pembrolizumab. Fourteen people with advanced epithelial cancers that had stopped responding to standard treatments received the combination. The main goal was to check safety and side effects, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NG-350A (a virus that targets tumors and activates immune cells) plus pembrolizumab (an immunotherapy drug)
What this could lead to: If this combination proves safe and shows signs of shrinking tumors, it could point toward a new treatment option for advanced epithelial cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 14 people, so it is designed mainly to check safety, not effectiveness. The approach may not work in larger studies, and side effects from the virus or immunotherapy could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma epithelial neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL TUMOR METASTATIC CANCER

Contacts and locations

Locations

Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

Oxford, Oxfordshire, OX3 7LE, United Kingdom
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Moffitt-Advent Health Clinical Research Unit

Celebration, Florida, 34747, United States
Perelman Center of Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States
Providence Medical Foundation

Santa Monica, California, 90404, United States
The Clatterbridge Cancer Centre NHS Foundation Trust

Liverpool, Lancashire, L7 8YA, United Kingdom
UCLA

Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.